Platelet-Rich Plasma for Hair Loss: How Strong Is the Evidence?

The pooled evidence points one way: platelet-rich plasma (PRP) modestly raises hair density in androgenetic alopecia. A 2024 meta-analysis in Anais Brasileiros de Dermatologia estimated roughly 28 more hairs per square centimeter versus control, and the result was statistically significant. That same analysis reported near-total statistical heterogeneity, rated the underlying studies as low quality, and documented evident publication bias. When those three problems sit beside a positive pooled estimate, the honest reading is that the direction of the effect is plausible while its true size stays uncertain.

What the pooled numbers say

The clearest recent appraisal comes from Kieling and colleagues, whose systematic review and meta-analysis of randomized clinical trials asked a narrow question: can autologous PRP increase hair density in androgenetic alopecia? Their review included 14 randomized trials covering 431 patients, of which 13 were pooled in the hair-density meta-analysis. The combined estimate for hair density was a mean difference of about 27.55 hairs per square centimeter, with a 95% confidence interval running from roughly 14 to 41. Hair diameter, by contrast, did not improve in a way the data could confirm; the pooled thickness effect crossed the line of no difference.

A newer and much larger 2025 systematic review in Dermatology and Therapy, by Anitua and colleagues, pulled together 43 randomized trials and 1,877 participants across alopecia types. It reported that activated PRP improved hair density and reduced recurrence versus placebo, and it graded the overall certainty as moderate rather than low. So two independent syntheses, built years apart from partly overlapping literature, both land on a positive density signal. That convergence is worth something. It is also where the easy part of the story ends.

Why a significant result can still be fragile

A pooled p-value under 0.05 tells you the combined estimate is unlikely to be pure chance. It says nothing about whether the studies deserved to be combined at all. This is where heterogeneity matters. Kieling and colleagues reported an I-squared near 96 percent for hair density. I-squared estimates the share of variation across studies that reflects real differences rather than sampling noise. A value that high means the individual trials were not measuring one stable effect; they were scattered widely, using different PRP preparations, injection schedules, follow-up windows, and counting methods. Averaging results that disagree this much produces a tidy central number that can misrepresent every trial feeding into it.

The quality rating compounds the problem. Using the GRADE framework, which downgrades evidence for risk of bias, inconsistency, imprecision, and other flaws, the 2024 analysis classified the body of evidence as low quality. Low-quality evidence means the estimated effect could shift substantially once better trials arrive. Small samples, weak blinding, and short follow-up all push reported benefits upward, and PRP trials have historically been small and hard to blind, since preparing and injecting a patient's own plasma is difficult to mask convincingly.

The publication bias problem

The third flag is the most quietly consequential. Kieling and colleagues found evident publication bias, meaning studies with positive PRP results appear more likely to have been published or found than studies showing nothing. When the negative and null trials are missing from the pool, the surviving literature tilts optimistic before a single calculation runs. A meta-analysis can only summarize what exists in the searchable record, so publication bias inflates the apparent benefit in a way that no amount of careful pooling can undo.

Reader-side incentives deserve a look too. PRP is an out-of-pocket aesthetic service in most settings, and some of the largest syntheses are produced by groups with commercial ties to PRP technology. That does not make their arithmetic wrong, but it is a reason to weight the independent, caveat-heavy appraisals heavily and to notice when a summary reads as reassuring while its own heterogeneity and bias statistics read as cautionary.

How to hold the evidence

Put the pieces together and a defensible summary emerges. PRP probably produces a real but modest increase in hair density in androgenetic alopecia, most consistently seen in trials of activated preparations. The magnitude reported in the literature is likely an overestimate, because the studies disagree wildly with one another, rate as low quality under GRADE, and sit atop a record skewed by publication bias. Thickness or caliber gains, which patients often care about as much as raw count, are not well supported. Both meta-analyses reach the same practical endpoint the authors themselves state: larger, standardized, well-blinded trials with harmonized PRP protocols are needed before the effect size can be trusted.

This article is educational and not medical advice. Whether PRP fits a given person depends on individual goals, alternatives with stronger evidence such as established topical and oral therapies, cost, and tolerance for a procedure whose benefit is real in direction but uncertain in size, and that judgment belongs to a person and their own clinician. A useful habit when reading any positive aesthetic claim is to check not only the headline effect but the three companions that decide how much it means: how consistent the studies were, how they scored on quality, and whether the published record is missing its failures.